Alto Neuroscience, Inc., a clinical-stage biopharmaceutical company focused on developing precision medicines for neuropsychiatric disorders, has appointed Dr. Raymond Sanchez to its Board of Directors, effective August 12, 2025. Dr. Sanchez brings over 20 years of experience in the life sciences industry along with a strong medical background.
Health Technology Insights: Provana Acquires MEG Business Management to Boost Wellness
Amit Etkin, M.D., Ph.D., founder and CEO of Alto Neuroscience, said, “We’re excited to have Ray join our Board of Directors as we continue to move forward with several clinical-stage precision psychiatry programs. Ray has a great history of leading the successful development of many CNS therapies, and his strategic insight will be very helpful as we prepare to start our potentially important Phase 2b trial of ALTO-207. Ray is a great addition to our board, and we believe his commitment to improving patient outcomes through innovation in psychiatry adds a lot to our mission.”
Health Technology Insights: Nodthera Shows Oral NLRP3 Inhibitor Reverses Parkinson’s Inflammation
Dr. Sanchez expressed his enthusiasm, saying, “As a psychiatrist, I’ve seen firsthand how little innovation has happened in this field, even though it’s one of the most pressing areas of unmet medical need. I’m thrilled to join Alto at this exciting time as the company works to change the standard of care by moving away from the outdated trial-and-error approach that has long been used in CNS drug development and clinical practice. With a strong late-stage pipeline and a strategy based on biology-driven precision medicine, I look forward to supporting Alto’s mission to provide new therapeutic solutions to the patients who need them most.”
Currently, Dr. Sanchez serves as a Senior Advisor at Bain Capital Life Sciences, a global investment firm, a position he has held since September 2024. Prior to this, he was Chief Medical Officer at Cerevel Therapeutics Holdings, Inc. from January 2019 until August 2024 when AbbVie acquired the company. Between 2007 and 2019, Dr. Sanchez held several senior roles at Otsuka Pharmaceutical Development & Commercialization, including Senior Vice President of Global Clinical Development starting in 2013.
From 2018 to 2019, he also served as Chief Medical Officer at Avanir Pharmaceuticals, which was later acquired by Otsuka America Pharmaceutical. Since November 2024, Dr. Sanchez has been a member of the board of directors at Rapport Therapeutics and holds board positions at several private biotechnology firms. Before entering the industry, he trained in psychiatry at Yale School of Medicine, where he was Chief Resident, a fellow, and an instructor.
Dr. Sanchez also served as executive co-chair of the International Society for CNS Drug Development from 2017 to 2022 and has contributed to organizations such as the Connecticut Mental Health Center Foundation and Yale School of Medicine. He earned a Bachelor of Arts in psychology from Northwestern University’s Weinberg College of Arts and Sciences and a medical degree from Northwestern’s Feinberg School of Medicine.
Health Technology Insights: Bionova Opens New pDNA Facility in Texas for Biopharma
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
